Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.00    1.00 (1.43%)
Bid:
70.00
Ask:
72.00
Spread: 2.00 (2.857%)
Market Cap: £323.13m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Appointment

9 Nov 2007 16:59

Avacta Group plc Board Appointment

Avacta Group plc ("Avacta" or the "Company"), which develops detection and analysis technology aimed at the biopharmaceutical, defence & security and clinical diagnostics markets, is pleased to announce the appointment of Russell Hodgetts to the Board of Directors, with effect from 10 July 2007.

Russell Winston Hodgetts, 36, has been Chief Operating Officer of Avacta since October 2005, and has a wealth of experience in strategic business development and group operations. Prior to joining Avacta he worked for Techtran Group Limited where he helped guide the commercialization and business development of companies created from University of Leeds research and intellectual property.

He currently oversees the development of the analytical services division of the Company in addition to being responsible for group operations.

Russell Hodgetts is the beneficial owner of 9,847,912 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"), representing approximately 1.27 per cent. of the issued share capital of the Company and 1,804,568 options to acquire Ordinary Shares at an exercise price of 2.25p per share.

He is also a director of Avacta Analytical Limited.

Russell Hodgetts was named Russell Beckett until family circumstances led to his name being changed when aged 11.

There are no other disclosures required by paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:

"Russell has been an integral part of the development of Avacta over the past two years and his focus on continued growth has been central to the success of Avacta Analytical Ltd. We are pleased to welcome him to the Board and will continue to draw on his knowledge and drive to ensure that Avacta maintains its current path of development and innovation."

9 November 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Limited Tel: 020 7562 4713 Henry Turcan/Michael Brennan Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk

AVACTA GROUP PLC
Date   Source Headline
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.